Wordt geladen...
The future of treatment for patients with relapsed/refractory multiple myeloma: The Future of Proteasome Inhibitors in Relapsed/Refractory Multiple Myeloma
The ubiquitin-proteasome pathway was first validated as a target for cancer therapy with the demonstration of the activity of the boronic acid proteasome inhibitor bortezomib against relapsed and relapsed/refractory multiple myeloma. Another generation of proteasome inhibitors is now entering the cl...
Bewaard in:
| Hoofdauteur: | |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2011
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4163602/ https://ncbi.nlm.nih.gov/pubmed/25188482 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|